Fig. 5: Impact of ALK alterations on patient survival.
From: Genomic ALK alterations in primary and relapsed neuroblastoma
a OS of patients with ALK-mutated tumors versus patients with ALK wildtype tumors at diagnosis (5-year OS, 66% versus 76%). b OS of high-risk patients with tumors harboring ALK mutations at allelic fractions >20% versus ≤ 20% versus ALK wildtype (5-year OS, 28% versus 57% versus 54%). c EFS of high-risk patients with tumors harboring ALK mutations at allelic fractions >20% versus ≤ 20% versus ALK wildtype (5-year EFS, 17% versus 57% versus 33%). d OS of patients with ALK-amplified tumors versus ALK non-amplified tumors at diagnosis (5-year OS, 22% versus 60%). e OS of patients with ALK-amplified versus non-amplified tumors at relapse (5-year OS, 0% versus 57%). f OS of patients with ALK-altered versus ALK-non-altered tumors at relapse (5-year OS, 37% versus 61%). P values were calculated by log-rank and, in case of non-proportional hazards, Gehan-Breslow test. OS, overall survival; y, years; ampl, amplification; AF, allelic fraction.
